Trial Profile
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Aug 2019
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 29 Jul 2019 A population pharmacokinetic analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat pharmacokinetics using pooled data from 6 clinical studies ; results published in the British Journal of Clinical Pharmacology
- 08 Apr 2016 Results published in the Investigational New Drugs
- 01 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.